PMC:7200337 / 95133-95294 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"3134","span":{"begin":144,"end":148},"obj":"Gene"}],"attributes":[{"id":"A3134","pred":"tao:has_database_id","subj":"3134","obj":"Gene:59272"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Four of the antibodies produced in these studies (31B5, 32D4, P2C-2F6, P2C-1F11) showed high neutralizing potential in vitro, and all inhibited ACE2-RBD binding."}

{"project":"LitCovid-sentences","denotations":[{"id":"T547","span":{"begin":0,"end":161},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Four of the antibodies produced in these studies (31B5, 32D4, P2C-2F6, P2C-1F11) showed high neutralizing potential in vitro, and all inhibited ACE2-RBD binding."}